Low Growth Hormone Symptoms: What Could Be Causing It?

What Growth Hormone Does and Why Deficiency Matters

Growth hormone (GH) is secreted in pulses from the anterior pituitary gland and acts directly on tissues and indirectly through insulin-like growth factor-1 (IGF-1), which is produced mainly in the liver. GH regulates body composition, bone density, lipid metabolism, glucose homeostasis, and cardiac function throughout adult life, not just during childhood growth. When GH secretion falls below physiological thresholds, every organ system that depends on it begins to show strain. Molitch ME et al., J Clin Endocrinol Metab, 2011 established the consensus framework still used today.

Why Adult GHD Is Underdiagnosed

Many of the symptoms of adult GHD overlap with hypothyroidism, depression, obstructive sleep apnea, and simple deconditioning. A patient complaining of fatigue and weight gain is far more likely to receive a thyroid panel than a GH stimulation test on a first visit. The Endocrine Society's 2011 clinical practice guideline notes that GHD "should be suspected in any patient with known pituitary disease, hypothalamic disease, or a history of cranial irradiation" before broader screening is considered. Molitch ME et al., 2011

The IGF-1 Connection

IGF-1 is the practical proxy for GH axis activity. Because GH itself is released in short overnight pulses, a random GH level is rarely useful. IGF-1, by contrast, has a half-life of 15 to 20 hours and reflects integrated GH secretion over days. A serum IGF-1 below the age-matched lower limit of normal is sensitive enough to prompt confirmatory stimulation testing, though it is not diagnostic on its own. Bidlingmaier M et al., 2014, Eur J Endocrinol reviewed the limitations of IGF-1 alone and found a specificity of roughly 87% for severe GHD in adults with structural pituitary disease.

Recognizing the Symptoms of Low Growth Hormone

The symptom pattern of adult GHD is diffuse and non-specific, which is exactly what makes it so easy to miss. No single symptom is pathognomonic, but the combination of central adiposity, fatigue, reduced exercise tolerance, and mood disturbance in a patient with pituitary risk factors should raise immediate suspicion.

Body Composition Changes

Increased visceral adiposity is the most consistent physical finding in adult GHD. KIMS (Pfizer International Metabolic Database), which tracked more than 13,983 adults with GHD across Europe and the United States, documented mean waist circumference increases of 4 to 6 cm over untreated follow-up periods. Feldt-Rasmussen U et al., 2004, J Clin Endocrinol Metab Muscle mass simultaneously declines: dual-energy X-ray absorptiometry (DEXA) studies show lean body mass roughly 5 to 10 kg below age-matched controls in confirmed GHD adults.

The fat redistribution in GHD is centrally driven, not peripheral. Patients may not look dramatically obese, but visceral fat volume on CT is consistently elevated, and this correlates with the dyslipidemia and insulin resistance that accompany the syndrome.

Fatigue and Exercise Intolerance

Adults with GHD report fatigue that is disproportionate to activity level. VO2 max values in GHD cohorts run approximately 20% below age-matched healthy controls, according to data compiled in Svensson J et al., 2003, Clin Endocrinol. Muscle weakness, particularly in proximal muscle groups, limits stair climbing, overhead work, and sustained aerobic effort.

Psychological and Cognitive Symptoms

Depression, anxiety, social withdrawal, and self-reported memory difficulties occur at significantly higher rates in GHD adults than in age-matched populations. The Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) questionnaire was validated specifically for this syndrome and consistently shows scores 8 to 12 points higher (worse) in untreated GHD than in healthy controls. McKenna SP et al., 1999, Qual Life Res

Bone and Cardiovascular Risk

Bone mineral density (BMD) decreases by roughly 1 standard deviation at the lumbar spine in long-standing adult GHD, increasing fracture risk. Cardiovascular risk is also elevated: Bülow B et al., 1997, J Clin Endocrinol Metab found a standardized mortality ratio of 2.0 (95% CI: 1.4 to 2.7) for cardiovascular death in hypopituitary patients with untreated GHD compared to the general population.

Causes of Low Growth Hormone: A Clinical Differential

When a patient presents with symptoms consistent with GHD, the workup must address the underlying etiology because cause shapes prognosis, testing strategy, and sometimes treatment intensity.

Pituitary Tumors and Their Treatment

Pituitary adenomas are the single most common cause of acquired adult GHD. The tumor itself can compress the somatotroph cells that produce GH, but surgical resection and cranial radiation are often equally or more damaging. Darzy KH, 2009, Eur J Endocrinol reported that GHD is the most radiation-sensitive of all pituitary axes: 50% of patients develop GHD within 5 years of receiving 30 to 50 Gy to the hypothalamic-pituitary axis, and 100% develop it within 10 years at doses above 50 Gy.

Non-functioning adenomas, prolactinomas, craniopharyngiomas, and Rathke's cleft cysts all carry significant GHD risk regardless of whether surgery is performed.

Traumatic Brain Injury

Traumatic brain injury (TBI) emerged as a major GHD cause only in the past two decades. The pituitary gland's blood supply runs through the pituitary stalk, which is vulnerable to shear forces during deceleration injuries. Benvenga S et al., 2000, J Clin Endocrinol Metab reviewed 367 published cases of post-traumatic hypopituitarism and found GHD was the most frequent hormone deficit, present in up to 40% of moderate-to-severe TBI survivors when formally tested. Mild TBI (concussion) carries a lower but non-negligible risk.

Childhood-Onset GHD Persisting Into Adulthood

Some adults presenting with GHD symptoms were diagnosed with GHD in childhood but either stopped treatment after linear growth was complete or were never retested. The Endocrine Society guideline recommends retesting all childhood GHD patients 1 to 3 months after stopping GH therapy. Approximately 40 to 60% of children with idiopathic GHD will have a normal GH response on adult retesting, meaning the childhood deficiency was transient. The remaining 40 to 60%, particularly those with structural pituitary defects or multiple pituitary hormone deficiencies, will have confirmed persistent adult GHD. Attanasio AF et al., 2002, J Clin Endocrinol Metab

Idiopathic and Functional GHD

A subset of patients, perhaps 10 to 20% of confirmed adult GHD cases, have no identifiable structural or historical cause. Obesity itself suppresses GH secretion significantly: visceral fat increases somatostatin tone and reduces GH pulse amplitude. This creates a diagnostic challenge because an obese patient may appear to have GHD on stimulation testing, yet the low GH may be functional rather than pathological. Repeat testing after meaningful weight loss, or use of the GHRH-arginine test (which is less suppressed by obesity than the ITT), helps clarify the picture. Corneli G et al., 2005, J Clin Endocrinol Metab

Other Structural and Infiltrative Causes

Empty sella syndrome, pituitary apoplexy, autoimmune hypophysitis (including the increasingly recognized checkpoint-inhibitor-induced hypophysitis), sarcoidosis, histiocytosis X, and hemochromatosis all damage somatotroph cells. These causes collectively account for a small percentage of GHD cases but should be considered in any patient with multi-axis pituitary disease or a systemic illness that targets the hypothalamus or pituitary.

How Low Growth Hormone Is Diagnosed

Diagnosis requires two parallel findings: a clinical picture consistent with GHD (ideally with a relevant history such as pituitary disease or TBI), and biochemical confirmation via stimulation testing. Relying on symptoms or IGF-1 alone leads to both overdiagnosis and underdiagnosis.

Screening With IGF-1

The first step is a morning fasting serum IGF-1. The result must be interpreted against an age-, sex-, and laboratory-specific reference range. A result more than 2 standard deviations below the mean for age is a strong indicator and warrants stimulation testing. A result within the normal range does not rule out GHD in a patient with known pituitary disease, because some patients with confirmed GHD maintain IGF-1 near the lower end of normal. Bidlingmaier M et al., 2014

Provocative Stimulation Tests

The insulin tolerance test (ITT) remains the gold standard. Blood glucose is lowered to <40 mg/dL via IV insulin, and GH is measured at 0, 30, 60, 90, and 120 minutes. A peak GH <3 µg/L confirms severe GHD in adults. The ITT is contraindicated in patients with seizure disorders, coronary artery disease, or age over 65. Yuen KC et al., 2021, J Clin Endocrinol Metab

The GHRH-arginine test (GHRH 1 µg/kg IV plus arginine 0.5 g/kg IV over 30 minutes) is the preferred alternative when ITT is contraindicated. BMI-adjusted cutoffs apply: peak GH <11 µg/L for BMI <25 kg/m², <8 µg/L for BMI 25 to 30 kg/m², and <4 µg/L for BMI >30 kg/m². Corneli G et al., 2005

Glucagon stimulation testing (1 mg IM, 1.5 mg if body weight >90 kg) is a widely available alternative now preferred by many US endocrinologists when GHRH is not commercially available. A peak GH <3 µg/L at 180 minutes supports the diagnosis. Yuen KC et al., 2021

Imaging

MRI of the pituitary gland with gadolinium contrast is standard practice once biochemical GHD is confirmed. It identifies adenomas, stalk lesions, empty sella, or structural hypothalamic abnormalities that explain the deficiency. In a patient with confirmed GHD and no prior pituitary history, an MRI finding of a structural lesion will change management in a significant proportion of cases.

Treatment Options for Low Growth Hormone

Recombinant Human Growth Hormone

Recombinant human growth hormone (somatropin) is the primary treatment for confirmed adult GHD. Multiple brand formulations exist (Genotropin, Humatrope, Norditropin, Saizen, Serostim, Omnitrope). All are administered as daily subcutaneous injections, typically in the evening to mimic the physiological overnight GH surge.

Starting doses for adults are intentionally low to minimize side effects: 0.1 to 0.2 mg/day in younger patients and 0.1 mg/day in older patients or those with diabetes risk. Doses are titrated every 4 to 8 weeks based on IGF-1 response, symptom improvement, and tolerability, targeting an IGF-1 in the upper half of the age-adjusted normal range. The FDA approved somatropin for adult GHD in 1996. FDA prescribing information for Genotropin

Expected Clinical Outcomes

The KIMS registry provided the largest real-world outcome dataset for adult GHD treatment. After 12 months of rhGH therapy, mean lean body mass increased by 3.5 kg, fat mass decreased by 4.0 kg, total cholesterol fell by 0.3 mmol/L, and QoL-AGHDA scores improved by a mean of 4.7 points. Feldt-Rasmussen U et al., 2004 These improvements were sustained at 5-year follow-up in adherent patients.

Bone mineral density improvements lag body composition changes. BMD gains at the lumbar spine typically require 18 to 24 months of therapy before becoming statistically significant on DEXA.

Side Effects and Monitoring

Common side effects include fluid retention (edema, arthralgias, carpal tunnel syndrome) and are dose-dependent and reversible with dose reduction. Glucose intolerance may worsen transiently. IGF-1 should be checked every 6 months once at steady state. A theoretical concern about GH increasing cancer risk is not supported by current registry data spanning 10 to 15 years of treatment, but active malignancy remains an absolute contraindication. van Bunderen CC et al., 2011, J Clin Endocrinol Metab

Tesamorelin: An Alternative Mechanism

Tesamorelin (Egrifta SV) is a synthetic GHRH analogue approved by the FDA for HIV-associated lipodystrophy. It stimulates endogenous GH secretion rather than replacing it. Off-label interest exists for its use in non-HIV GHD contexts, but current evidence does not support routine substitution for rhGH in pituitary-origin GHD. FDA label for Egrifta SV

When to Refer and What to Expect

Any patient with documented pituitary disease, prior cranial radiation, moderate-to-severe TBI, or an unexplained cluster of fatigue, central obesity, and dyslipidemia warrants an endocrinology referral. The Endocrine Society guideline specifies that GH stimulation testing is appropriate for patients with "three or more pituitary hormone deficiencies and a low IGF-1, who may be considered GHD without additional testing." Molitch ME et al., 2011

The HealthRX clinical team uses a three-tier evaluation path for patients presenting with suspected GHD:

Tier 1 (Any primary care setting): Morning fasting IGF-1, comprehensive metabolic panel, thyroid-stimulating hormone, free T4, cortisol AM, prolactin, and LH/FSH. Rule out common mimics first.

Tier 2 (Endocrinology referral): GH stimulation test selected by the clinician based on patient's BMI, cardiovascular history, and GHRH availability. Pituitary MRI if not already obtained.

Tier 3 (Confirmed GHD, treatment initiation): Start somatropin at 0.1 to 0.2 mg/day, check IGF-1 and fasting glucose at 4 to 6 weeks, titrate every 4 to 8 weeks. Re-evaluate DEXA at baseline and 24 months.

Conditions That Mimic Low Growth Hormone Symptoms

Before ordering a GH stimulation test, rule out conditions that produce an overlapping symptom profile:

• Hypothyroidism: TSH and free T4 resolve the question within 24 hours. Fatigue and weight gain are the dominant overlapping features.
• Hypogonadism: Low testosterone in men and estrogen deficiency in women both cause muscle loss, central fat gain, and mood disturbance. A full sex hormone panel is mandatory in the GHD workup.
• Adrenal insufficiency: Morning cortisol below 3 µg/dL or a blunted ACTH stimulation test will flag this. Fatigue and reduced exercise tolerance dominate.
• Major depressive disorder: Depression's fatigue, weight change, and cognitive symptoms overlap nearly completely with GHD. The presence of a pituitary risk factor or very low IGF-1 tips toward biochemical testing.
• Obstructive sleep apnea: OSA suppresses GH secretion and produces fatigue, cognitive slowing, and weight gain. Treating OSA can normalize GH pulsatility in some patients.
• Celiac disease: Malabsorption drives low IGF-1 independent of GH secretion. Tissue transglutaminase IgA should be checked when IGF-1 is low and no pituitary history exists.

Thyroid function should be normal before any GH stimulation test is performed, because hypothyroidism blunts GH response and produces false-positive results. Yuen KC et al., 2021